Publications by authors named "J Gerdts"
Article Synopsis
- The review covers the genetic and epigenetic factors related to food allergies, including their inheritance and the advantages and limitations of study methods.
- Genome-wide association studies have identified 16 significant genetic variants linked to food allergies, often overlapping with other allergic conditions.
- The article emphasizes the importance of integrating genetic and epigenetic data for understanding disease mechanisms and suggests future implications for predicting food allergy risks and responses to treatment.
This Anaphylaxis Manifesto calls on communities to prioritise 10 practical actions to improve the lives of people at risk of serious allergic reactions. The Global Allergy and Asthma European Network and the European Federation of Allergy and Airways Diseases Patients' Associations (EFA) compiled patient-centric priorities. We used qualitative consensus methods, research evidence and feedback from over 200 patient groups, stakeholder organisations and healthcare professionals.
View Article and Find Full Text PDFBackground: Progressive multifocal leukoencephalopathy (PML) is a frequently fatal disease of the central nervous system caused by JC virus (JCV). Survival is dependent on early diagnosis and ability to re-establish anti-viral T cell immunity. Adoptive transfer of polyomavirus-specific T cells has shown promise; however, there are no readily available HLA-matched anti-viral T cells to facilitate rapid treatment.
View Article and Find Full Text PDFIntroduction: Anaphylaxis is an acute life-threatening allergy, most commonly provoked by food, venom, or drugs. There is limited data regarding differences in symptomatology between anaphylaxis provoked by different triggers. This study aimed to assess sociodemographic characteristics, clinical symptoms, and management of anaphylaxis, according to triggers in adults.
View Article and Find Full Text PDFArticle Synopsis
- IgE-mediated food allergies are the most common type, causing quick and serious reactions that affect patients' and caregivers' lives.
- Omalizumab is a humanized monoclonal antibody that binds to IgE, reducing allergic reactions, and has been approved by the FDA for treating these food allergies.
- The GALEN ANACARE Consensus Statement supports omalizumab's use based on a systematic review and expert agreement, noting it is currently the only drug that can significantly reduce IgE-mediated food allergic reactions, although more evidence is needed for stronger guideline recommendations.